This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Reasons to Add HealthEquity Stock to Your Portfolio for Now
by Zacks Equity Research
HQY's strong Q2, expanding HSAs and AI-driven efficiencies highlight its growth momentum despite data security risks.
MASINegative Net Change MMSINegative Net Change WSTNegative Net Change HQYNegative Net Change
medical medical-devices
J&J Bets on MedTech Growth With Orthopaedics Unit Spin-Off Plan
by Kinjel Shah
J&J's surprise plan to spin off its Orthopaedics unit as DePuy Synthes is aimed at sharpening MedTech focus and boosting growth margins.
JNJNegative Net Change MDTNegative Net Change SYKNegative Net Change KVUENegative Net Change
medical medical-devices pharmaceuticals
Hims & Hers Elevates Technology-Driven Healthcare Accessibility
by Debanjana Dey
HIMS boosts AI-led care with new technology chief, hormone therapies and a global push via its ZAVA acquisition.
TDOCNegative Net Change HIMSNegative Net Change TEMNegative Net Change
medical medical-devices
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan
by Zacks Equity Research
VTRS acquires Aculys Pharma to boost its CNS portfolio in Japan, gaining rights to pitolisant and Spydia for narcolepsy and seizure management, respectively.
ALNYPositive Net Change ANIPNegative Net Change VTRSNegative Net Change CMMBPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio
by Zacks Equity Research
Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.
NVONegative Net Change LLYNegative Net Change OMERPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Add CVS Health Stock to Your Portfolio Before Q3 Earnings?
by Moumi Mondal
CVS Health prepares Q3 results, with pharmacy performance and Aetna's progress in focus for investors.
UNHPositive Net Change CVSPositive Net Change ELVPositive Net Change
earnings-preview medical medical-devices
How Will Mounjaro and Zepbound Sales Aid Lilly's Upcoming Q3 Results?
by Sundeep Ganoria
Strong demand for Mounjaro and Zepbound is expected to power LLY's Q3 growth, as both drugs deepen U.S. and global market reach.
NVONegative Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
Merit Medical Expands GI Portfolio With $22M C2 CryoBalloon Acquisition
by Zacks Equity Research
MMSI is set to acquire C2 CryoBalloon from Pentax for $22M, strengthening its GI portfolio. Despite near-term dilution, the deal positions Merit for long-term growth in gastroenterology.
MASINegative Net Change MMSINegative Net Change DRIONegative Net Change NDRANegative Net Change
medical medical-devices
ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook
by Aparajita Dutta
JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.
JNJNegative Net Change XLVNegative Net Change IYHNegative Net Change IHENegative Net Change FHLCNegative Net Change FTXHNegative Net Change
etfs medical
NVS Reports Positive Late-Stage Data on Kidney Disease Drug
by Zacks Equity Research
Novartis' Fabhalta shows strong phase III results in slowing IgA nephropathy progression, paving the way for full FDA approval in 2026.
NVSNegative Net Change BAYRYNegative Net Change TVTXPositive Net Change TRMLNo Net Change
biotechnology medical pharmaceuticals
TMO to Report Q3 Earnings: Life Science Solutions Segment in Focus
by Zacks Equity Research
Thermo Fisher's Q3 results on Oct. 22 are set to spotlight gains from new launches and acquisitions across key growth segments.
TMONegative Net Change IDXXNegative Net Change ANIPNegative Net Change EXASNegative Net Change
earnings medical
Will Robust Cardiovascular Performance Fuel BSX's Q3 Earnings?
by Zacks Equity Research
Boston Scientific's strong cardiovascular and MedSurg momentum, powered by innovations like WATCHMAN FLX Pro and AGENT DCB, could drive solid Q3 results.
BSXNegative Net Change IDXXNegative Net Change ANIPNegative Net Change EXASNegative Net Change
earnings medical
Company News for Oct 16, 2025
by Zacks Equity Research
Companies In The News Are: HWC, PGR, ABT, ASML.
ABTNegative Net Change ASMLNegative Net Change PGRNegative Net Change HWCPositive Net Change
finance insurance medical semiconductor
Zacks Industry Outlook Highlights HCA Healthcare, Universal Health Services and Community Health Systems
by Zacks Equity Research
Zacks spotlights HCA Healthcare, Universal Health Services, and Community Health Systems as resilient players navigating rising costs and regulatory challenges in the hospital sector.
UHSPositive Net Change CYHNegative Net Change HCANegative Net Change
medical
Zacks.com featured highlights include United Natural Foods, Teladoc Health, Supernus and BRP
by Zacks Equity Research
Zacks highlights United Natural Foods, Teladoc Health, Supernus, and BRP as strong relative price strength stocks positioned to outperform in volatile markets.
UNFINegative Net Change SUPNPositive Net Change TDOCNegative Net Change DOOONegative Net Change
medical
Zacks.com featured highlights include StoneCo, PagSeguro Digital, KT, Arrow Electronics and CVS Health
by Zacks Equity Research
Zacks spotlights StoneCo, PagSeguro Digital, KT, Arrow Electronics, and CVS Health as attractive low price-to-book stocks with strong growth prospects.
KTPositive Net Change ARWNegative Net Change CVSPositive Net Change PAGSNegative Net Change STNENegative Net Change
medical
Top Research Reports for UBS, Newmont & McKesson
by Mark Vickery
UBS advances on solid earnings and integration progress, while Newmont and McKesson deliver strong gains through expansion and operational efficiency.
NRGPositive Net Change UBSPositive Net Change MCKNegative Net Change NEMPositive Net Change CATONegative Net Change SHOPPositive Net Change OTISNegative Net Change
finance gold medical retail
Can 4 Relative Price Strength Stocks Defy Market Swings?
by Nilanjan Choudhury
UNFI, TDOC, SUPN and BRP shine with strong relative price strength, earnings momentum, and analyst upgrades amid volatile markets.
UNFINegative Net Change SUPNPositive Net Change TDOCNegative Net Change DOOONegative Net Change
auto-tires-trucks consumer-staples medical
GEHC Stock Up Following New Launch to Streamline Perinatal Workflow
by Zacks Equity Research
GE HealthCare unveils CareIntellect for Perinatal, a SaaS tool aimed at improving maternal and fetal care delivery.
RMDNegative Net Change HCANegative Net Change GEHCPositive Net Change SOLVNegative Net Change
medical medical-devices
Will Rising Costs Hurt Elevance's Q3 Earnings Despite Higher Premiums?
by Zacks Equity Research
ELV's third-quarter earnings may face pressure as rising costs and weaker Medicaid memberships offset premium gains.
CVSPositive Net Change SEMPositive Net Change NVSTNegative Net Change ELVPositive Net Change
earnings insurance medical
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
by Zacks Equity Research
VEEV's strong Q2, expanding AI strategy and major life sciences partnerships fuel growth despite rising costs.
MASINegative Net Change MMSINegative Net Change WSTNegative Net Change VEEVNegative Net Change
medical medical-devices
CORT Files MAA for Relacorilant in Platinum-Resistant Ovarian Cancer
by Zacks Equity Research
Corcept files a marketing application with the EMA for relacorilant in platinum-resistant ovarian cancer after studies show survival gains.
RHHBYNegative Net Change CORTNegative Net Change ANIPNegative Net Change CMMBPositive Net Change
medical
5 Low Price-to-Book Stocks Worth Considering in October
by Kinjel Shah
STNE, CVS, KT, PAGS and ARW are five low price-to-book stocks that combine value appeal with solid growth potential.
KTPositive Net Change ARWNegative Net Change CVSPositive Net Change PAGSNegative Net Change STNENegative Net Change
business-services computers medical
Hospital Market Sneezing, But These 3 Stocks Avoiding the Cold
by Kaibalya Pravo Dey
HCA, UHS and CYH are showing strength through rising volumes and occupancy despite hospital industry headwinds.
HCANegative Net Change UHSPositive Net Change CYHNegative Net Change
hospitals medical
Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock?
by Zacks Equity Research
Investors need to pay close attention to ALNY stock based on the movements in the options market lately.
ALNYPositive Net Change
medical